MedTrace Logo

Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity

NCT06431932 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-19

No results posted yet for this study

Summary

The accumulation of senescent cells with age is a central mechanism that contributes to the development of chronic diseases, primarily by driving systemic chronic inflammation. Senolytic compounds such as fisetin can selectively target senescent cells for elimination and reduce multiple age-related pathologies in animal models.

We will conduct a clinical trial in healthy volunteers and older patients with multiple chronic diseases. The participants will receive fisetin or placebo for two days, after which they will be examined at regular intervals for up to three months. We will investigate how fisetin is absorbed and metabolized by the body, and whether fisetin is safe. We will also identify methods to best measure the effect of fisetin on chronic inflammation, senescent cells, and general health.

Conditions

  • Multimorbidity
  • Healthy

Interventions

DRUG

Fisetin

Subjects will receive fisetin corresponding to 20 mg/kg/day for two consecutive days.

DRUG

Placebo

Subjects will receive a corresponding number of placebo capsules for two consecutive days.

Sponsors & Collaborators

  • University of Southern Denmark

    collaborator OTHER

  • Mayo Clinic

    collaborator OTHER

  • Ove Andersen

    lead OTHER

Principal Investigators

  • Juliette Tavenier · Copenhagen University Hospital, Amager and Hvidovre

  • Line Jee Hartmann Rasmussen · Copenhagen University Hospital, Amager and Hvidovre

  • Morten B Houlind · Copenhagen University Hospital, Amager and Hvidovre

  • Ove Andersen · Copenhagen University Hospital, Amager and Hvidovre

  • Jan O Nehlin · Copenhagen University Hospital, Amager and Hvidovre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-24
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06431932 on ClinicalTrials.gov